menu
    • menu

    Company profile for Incyclix Bio

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Incyclix Bio is advancing next-generation precision treatments to regain control of the cell cycle where aberrant proliferation is a fundamental driver of many cancers. We believe the CDK family is a rich source of of novel cancer targets worthy of drug development. Our team is applying its unsurpassed expertise and deep knowledge of CDK inhibitors to bring hope to people with advanced and resistant cancers. Dysregulated kinas...
    Incyclix Bio is advancing next-generation precision treatments to regain control of the cell cycle where aberrant proliferation is a fundamental driver of many cancers. We believe the CDK family is a rich source of of novel cancer targets worthy of drug development. Our team is applying its unsurpassed expertise and deep knowledge of CDK inhibitors to bring hope to people with advanced and resistant cancers. Dysregulated kinase activity of specific CDK family members drives uncontrolled cellular proliferation – a hallmark of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Incyclix BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    600 Park Offices Dr., Suite 355 Research Triangle Park, NC 27709
    Telephone
    Telephone
    (919) 328-0003
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://incyclixbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/incyclix-bio-llc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyclix Bio Boost Funding by $11.25M for INX-315 Phase 1/2 Trial
    Incyclix Bio Boost Funding by $11.25M for INX-315 Phase 1/2 Trial

    25 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/25/3138346/0/en/Incyclix-Bio-Secures-11-25-Million-Series-B-Extension-to-Advance-the-Phase-1-2-Clinical-Trial-of-INX-315-in-Patients-with-CDK4-6-Inhibitor-Resistant-ER-HER2-Breast-Cancer-or-CCNE1-.html

    GLOBENEWSWIRE
    25 Aug 2025
    Share Share
    Incyclix Bio Granted FDA Fast Track for INX-315 in Ovarian Cancer
    Incyclix Bio Granted FDA Fast Track for INX-315 in Ovarian Cancer

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070088/0/en/Incyclix-Bio-Granted-U-S-FDA-Fast-Track-Designation-for-INX-315-to-Treat-CCNE1-Amplified-Platinum-Resistant-Refractory-Ovarian-Cancer.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Incyclix Bio Publishes CDK2 Inhibition Biomarkers Response
    Incyclix Bio Publishes CDK2 Inhibition Biomarkers Response

    13 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/13/3025828/0/en/Incyclix-Bio-Announces-Publication-in-Nature-Communications-Highlighting-Biomarkers-of-Response-to-CDK2-Inhibition.html

    GLOBENEWSWIRE
    13 Feb 2025
    Share Share
    Incyclix Shares INX-315 Phase 1/2 Data For Resistant Cancers
    Incyclix Shares INX-315 Phase 1/2 Data For Resistant Cancers

    13 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/13/2996733/0/en/Incyclix-Bio-Announces-Interim-Clinical-Data-from-the-Phase-1-2-Clinical-Trial-of-INX-315-in-Patients-with-CDK4-6-Inhibitor-Resistant-ER-HER2-Breast-Cancer-or-CCNE1-Amplified-Solid.html

    GLOBENEWSWIRE
    13 Dec 2024
    Share Share
    Incyclix Bio Announces Trial Collaboration with Lilly for INX-315
    Incyclix Bio Announces Trial Collaboration with Lilly for INX-315

    18 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/18/2982655/0/en/Incyclix-Bio-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Lilly-to-Evaluate-INX-315-in-Combination-with-Verzenio-abemaciclib-and-Fulvestrant-in-HR-HER2-Breast-C.html

    GLOBENEWSWIRE
    18 Nov 2024
    Share Share
    Incyclix Bio Expands Board of Directors with Appointment of Norman
    Incyclix Bio Expands Board of Directors with Appointment of Norman

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2978967/0/en/Incyclix-Bio-Expands-Board-of-Directors-with-Appointment-of-Norman-E-Sharpless-MD.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search